JP2013512678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512678A5 JP2013512678A5 JP2012542240A JP2012542240A JP2013512678A5 JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5 JP 2012542240 A JP2012542240 A JP 2012542240A JP 2012542240 A JP2012542240 A JP 2012542240A JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- factor viii
- amino acids
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 159
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 130
- 229920001184 polypeptide Polymers 0.000 claims description 129
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 129
- 108010054218 Factor VIII Proteins 0.000 claims description 114
- 102000001690 Factor VIII Human genes 0.000 claims description 114
- 229960000301 factor viii Drugs 0.000 claims description 114
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 30
- 208000032843 Hemorrhage Diseases 0.000 claims description 26
- 208000034158 bleeding Diseases 0.000 claims description 26
- 230000000740 bleeding effect Effects 0.000 claims description 26
- 238000001356 surgical procedure Methods 0.000 claims description 21
- 238000011287 therapeutic dose Methods 0.000 claims description 21
- 238000011084 recovery Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 5
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000029836 Inguinal Hernia Diseases 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 3
- 238000007428 craniotomy Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000013150 knee replacement Methods 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 238000007483 tonsillectomy Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000002297 emergency surgery Methods 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 88
- 108010076504 Protein Sorting Signals Proteins 0.000 description 43
- 108010014173 Factor X Proteins 0.000 description 21
- 108090001015 cancer procoagulant Proteins 0.000 description 15
- 108010048049 Factor IXa Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 229960000900 human factor viii Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010072043 Central nervous system haemorrhage Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010028024 Mouth haemorrhage Diseases 0.000 description 2
- 206010028309 Muscle haemorrhage Diseases 0.000 description 2
- 208000009613 Oral Hemorrhage Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000000574 retroperitoneal space Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26707009P | 2009-12-06 | 2009-12-06 | |
| US61/267,070 | 2009-12-06 | ||
| US28505409P | 2009-12-09 | 2009-12-09 | |
| US61/285,054 | 2009-12-09 | ||
| US30159210P | 2010-02-04 | 2010-02-04 | |
| US61/301,592 | 2010-02-04 | ||
| US36306510P | 2010-07-09 | 2010-07-09 | |
| US61/363,065 | 2010-07-09 | ||
| US37311310P | 2010-08-12 | 2010-08-12 | |
| US61/373,113 | 2010-08-12 | ||
| US41092910P | 2010-11-07 | 2010-11-07 | |
| US61/410,929 | 2010-11-07 | ||
| US41967610P | 2010-12-03 | 2010-12-03 | |
| US61/419,676 | 2010-12-03 | ||
| PCT/US2010/059136 WO2011069164A2 (en) | 2009-12-06 | 2010-12-06 | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Division JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512678A JP2013512678A (ja) | 2013-04-18 |
| JP2013512678A5 true JP2013512678A5 (enExample) | 2013-12-26 |
| JP5903048B2 JP5903048B2 (ja) | 2016-04-13 |
Family
ID=44115536
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542240A Active JP5903048B2 (ja) | 2009-12-06 | 2010-12-06 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9050318B2 (enExample) |
| EP (4) | EP4382170A3 (enExample) |
| JP (8) | JP5903048B2 (enExample) |
| KR (1) | KR101770849B1 (enExample) |
| CN (1) | CN102791285A (enExample) |
| AU (6) | AU2010325787B2 (enExample) |
| BR (1) | BR112012013502A2 (enExample) |
| CA (2) | CA3121739A1 (enExample) |
| CO (1) | CO6561782A2 (enExample) |
| CY (2) | CY1119919T1 (enExample) |
| DK (1) | DK2506868T3 (enExample) |
| EA (2) | EA025416B1 (enExample) |
| ES (2) | ES2659888T3 (enExample) |
| HR (2) | HRP20180135T1 (enExample) |
| HU (1) | HUE036233T2 (enExample) |
| IL (2) | IL220204B (enExample) |
| LT (1) | LT2506868T (enExample) |
| ME (1) | ME02964B (enExample) |
| MX (3) | MX382693B (enExample) |
| MY (1) | MY159135A (enExample) |
| NO (1) | NO2506868T3 (enExample) |
| NZ (2) | NZ600709A (enExample) |
| PL (2) | PL3326643T3 (enExample) |
| PT (2) | PT3326643T (enExample) |
| RS (1) | RS56957B1 (enExample) |
| SG (3) | SG181130A1 (enExample) |
| SI (1) | SI2506868T1 (enExample) |
| SM (1) | SMT201800099T1 (enExample) |
| WO (1) | WO2011069164A2 (enExample) |
| ZA (1) | ZA201204874B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| EP4382170A3 (en) | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| PT2591006T (pt) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CA2838833A1 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| EP4169525A1 (en) * | 2011-07-08 | 2023-04-26 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
| EA028914B1 (ru) * | 2011-07-25 | 2018-01-31 | Байоджен Хемофилия Инк. | Исследования для мониторинга нарушений свертываемости крови |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| EA038705B1 (ru) * | 2012-01-12 | 2021-10-07 | Биовератив Терапьютикс Инк. | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii |
| HRP20191920T1 (hr) * | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| CN111548418A (zh) * | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP3521321B1 (en) | 2012-04-11 | 2020-11-04 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
| AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| US10023628B2 (en) * | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| ES2770501T3 (es) * | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| WO2014018777A2 (en) | 2012-07-25 | 2014-01-30 | Biogen Idec Ma Inc. | Blood factor monitoring assay and uses thereof |
| AU2013331000B2 (en) | 2012-10-18 | 2018-04-19 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| WO2014070953A1 (en) * | 2012-10-30 | 2014-05-08 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| RS61387B2 (sr) * | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| ES2926798T3 (es) * | 2013-03-15 | 2022-10-28 | Bioverativ Therapeutics Inc | Formulaciones de polipéptido de factor VIII |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3003368A4 (en) | 2013-05-24 | 2017-05-03 | Biogen MA Inc. | Anti-gpiib/iiia antibodies or uses thereof |
| TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途 |
| EA037962B1 (ru) * | 2013-06-20 | 2021-06-16 | Баксалта Инкорпорейтед | Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства |
| KR20230007555A (ko) * | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| HK1223303A1 (zh) * | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 凝血酶可裂解连接子 |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| US10325687B2 (en) * | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| NZ722391A (en) | 2014-02-04 | 2022-12-23 | Biogen Ma Inc | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| WO2015148454A1 (en) * | 2014-03-28 | 2015-10-01 | Asklepios Biopharmaceutical, Inc. | Optimized and modified factor viii genes for gene therapy |
| KR20190072663A (ko) | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| WO2017070167A1 (en) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| CN109804432B (zh) | 2016-04-15 | 2023-07-14 | 武田药品工业株式会社 | 提供药代动力学药物给药方案的方法和设备 |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| BR112019002039A2 (pt) | 2016-08-05 | 2019-05-07 | Medimmune, Llc | anticorpos anti-o2 e uso dos mesmos |
| CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CA3039686A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| CN108239151B (zh) * | 2016-12-23 | 2020-07-03 | 海门晟斯生物制药有限公司 | 重组单链人FVIII-Fc融合蛋白及其应用 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| BR112019015569A2 (pt) | 2017-01-31 | 2020-03-17 | Bioverativ Therapeutics Inc. | Proteínas de fusão do fator ix e métodos para a sua produção e uso |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| MA52783A (fr) | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
| EP3850006A1 (en) | 2018-09-11 | 2021-07-21 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
| AU2020298233A1 (en) | 2019-06-19 | 2022-01-20 | Bioverativ Therapeutics Inc. | Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| IL316578A (en) * | 2022-04-28 | 2024-12-01 | Biocad Joint Stock Co | Isolated nucleic acid encoding a FVIII-BDD-based coupling protein and a heterologous signal peptide |
| CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235881A (en) * | 1978-12-04 | 1980-11-25 | Cort Joseph H | Method for producing high potency factor VIII |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| MX9203440A (es) | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| ATE87663T1 (de) | 1986-01-03 | 1993-04-15 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ- proteinen. |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2437015A1 (en) * | 2001-02-05 | 2002-08-15 | Novo Nordisk Health Care Ag | Combined use of factor vii polypeptides and factor ix polypeptides |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| SI1624891T2 (sl) * | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CN1863556B (zh) * | 2003-06-19 | 2012-05-16 | 吉宁特有限公司 | 用于治疗凝血相关紊乱的组合物和方法 |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK2371856T3 (en) | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| US20130189239A1 (en) * | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| US8800831B2 (en) | 2009-08-19 | 2014-08-12 | Larry A. Gray | Multi-purpose rack and method thereof |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| EP2411024A4 (en) * | 2009-03-24 | 2013-02-27 | Bayer Healthcare Llc | Variants of factor viii and associated methods of use |
| GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| EP4382170A3 (en) | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| EP4169525A1 (en) | 2011-07-08 | 2023-04-26 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
| EA038705B1 (ru) * | 2012-01-12 | 2021-10-07 | Биовератив Терапьютикс Инк. | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii |
| ES2926798T3 (es) * | 2013-03-15 | 2022-10-28 | Bioverativ Therapeutics Inc | Formulaciones de polipéptido de factor VIII |
| JP6083911B2 (ja) | 2014-12-19 | 2017-02-22 | 花王株式会社 | 吸収性物品 |
-
2010
- 2010-12-06 EP EP24152910.6A patent/EP4382170A3/en active Pending
- 2010-12-06 EP EP10835255.0A patent/EP2506868B1/en active Active
- 2010-12-06 ES ES10835255.0T patent/ES2659888T3/es active Active
- 2010-12-06 US US13/513,424 patent/US9050318B2/en active Active
- 2010-12-06 NZ NZ600709A patent/NZ600709A/en unknown
- 2010-12-06 ES ES17194648T patent/ES2880038T3/es active Active
- 2010-12-06 PT PT171946486T patent/PT3326643T/pt unknown
- 2010-12-06 KR KR1020127017595A patent/KR101770849B1/ko active Active
- 2010-12-06 MX MX2018000089A patent/MX382693B/es unknown
- 2010-12-06 DK DK10835255.0T patent/DK2506868T3/da active
- 2010-12-06 CA CA3121739A patent/CA3121739A1/en active Pending
- 2010-12-06 EA EA201290443A patent/EA025416B1/ru not_active IP Right Cessation
- 2010-12-06 BR BR112012013502A patent/BR112012013502A2/pt not_active Application Discontinuation
- 2010-12-06 NO NO10835255A patent/NO2506868T3/no unknown
- 2010-12-06 NZ NZ703153A patent/NZ703153A/en unknown
- 2010-12-06 PT PT108352550T patent/PT2506868T/pt unknown
- 2010-12-06 HR HRP20180135TT patent/HRP20180135T1/hr unknown
- 2010-12-06 MY MYPI2012002429A patent/MY159135A/en unknown
- 2010-12-06 SG SG2012039640A patent/SG181130A1/en unknown
- 2010-12-06 EP EP21161784.0A patent/EP3906937A1/en not_active Ceased
- 2010-12-06 PL PL17194648T patent/PL3326643T3/pl unknown
- 2010-12-06 ME MEP-2018-40A patent/ME02964B/me unknown
- 2010-12-06 PL PL10835255T patent/PL2506868T3/pl unknown
- 2010-12-06 JP JP2012542240A patent/JP5903048B2/ja active Active
- 2010-12-06 SM SM20180099T patent/SMT201800099T1/it unknown
- 2010-12-06 RS RS20180182A patent/RS56957B1/sr unknown
- 2010-12-06 AU AU2010325787A patent/AU2010325787B2/en active Active
- 2010-12-06 SG SG10201907152YA patent/SG10201907152YA/en unknown
- 2010-12-06 CN CN2010800629507A patent/CN102791285A/zh active Pending
- 2010-12-06 MX MX2016000039A patent/MX353233B/es unknown
- 2010-12-06 EA EA201691109A patent/EA038618B1/ru unknown
- 2010-12-06 MX MX2012006347A patent/MX336830B/es active IP Right Grant
- 2010-12-06 SI SI201031628T patent/SI2506868T1/en unknown
- 2010-12-06 EP EP17194648.6A patent/EP3326643B1/en active Active
- 2010-12-06 SG SG10201408049SA patent/SG10201408049SA/en unknown
- 2010-12-06 WO PCT/US2010/059136 patent/WO2011069164A2/en not_active Ceased
- 2010-12-06 CA CA2782424A patent/CA2782424C/en active Active
- 2010-12-06 HU HUE10835255A patent/HUE036233T2/hu unknown
- 2010-12-06 LT LTEP10835255.0T patent/LT2506868T/lt unknown
-
2012
- 2012-06-06 IL IL220204A patent/IL220204B/en active IP Right Grant
- 2012-06-29 ZA ZA2012/04874A patent/ZA201204874B/en unknown
- 2012-06-29 CO CO12109855A patent/CO6561782A2/es unknown
-
2013
- 2013-03-11 US US13/793,783 patent/US9241978B2/en active Active
-
2015
- 2015-01-26 JP JP2015012409A patent/JP6062459B2/ja active Active
- 2015-12-09 US US14/964,289 patent/US20160199455A1/en not_active Abandoned
-
2016
- 2016-08-11 AU AU2016213822A patent/AU2016213822B2/en active Active
- 2016-10-26 JP JP2016209535A patent/JP6385410B2/ja active Active
-
2017
- 2017-11-15 JP JP2017220060A patent/JP6641340B2/ja active Active
- 2017-11-30 AU AU2017268648A patent/AU2017268648B2/en active Active
-
2018
- 2018-02-14 CY CY20181100182T patent/CY1119919T1/el unknown
- 2018-07-25 IL IL260769A patent/IL260769B/en active IP Right Grant
-
2019
- 2019-02-07 US US16/270,302 patent/US11266720B2/en active Active
- 2019-04-29 AU AU2019202969A patent/AU2019202969A1/en not_active Abandoned
- 2019-11-07 JP JP2019202433A patent/JP2020019821A/ja not_active Withdrawn
-
2021
- 2021-05-07 AU AU2021202912A patent/AU2021202912B2/en active Active
- 2021-06-28 HR HRP20211010TT patent/HRP20211010T1/hr unknown
- 2021-07-07 CY CY20211100615T patent/CY1124888T1/el unknown
-
2022
- 2022-01-28 US US17/587,941 patent/US20220265780A1/en active Pending
- 2022-02-14 JP JP2022020759A patent/JP7244688B2/ja active Active
-
2023
- 2023-03-09 JP JP2023036392A patent/JP2023071969A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227757A patent/AU2024227757A1/en active Pending
-
2025
- 2025-03-10 JP JP2025037046A patent/JP2025083451A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534426A5 (enExample) | ||
| JP2022051964A5 (enExample) | ||
| JP2012529296A5 (enExample) | ||
| EP2823823B1 (en) | Polypeptides for the preparation of drugs for treatment or prevention of rheumatoid arthritis | |
| CN102906120B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
| JP2014506787A5 (enExample) | ||
| CN112996913A (zh) | 寡聚核酸分子及其应用 | |
| US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
| JP2007536891A5 (enExample) | ||
| JP2016535015A (ja) | 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法 | |
| EP3647320B1 (en) | Acetylcholine receptor-binding peptide | |
| KR20260035821A (ko) | 조작된 gcn4 삼량체화 모티프 | |
| US20230055021A1 (en) | Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics | |
| JP7016125B2 (ja) | 脳梗塞の治療薬 | |
| RU2851806C1 (ru) | Композиции и способы их применения для лечения амиотрофического латерального склероза (als) | |
| CN104640557A (zh) | 骨保护素衍生的组合物及其用途 | |
| HK40115251A (en) | Method for treating fibrosis and arrhythmia with neuregulin-1 fusion protein | |
| WO2024149697A1 (en) | Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction | |
| CN121555454A (zh) | 抗黄病毒蛋白或多肽及其用途 | |
| JP5439007B2 (ja) | 血管内皮細胞増殖因子阻害剤及び抗癌剤 | |
| CN101469028A (zh) | 肿瘤坏死因子受体-免疫球蛋白的融合蛋白用于肺癌药物的用途 | |
| HK1160650A (en) | Antagonists against interaction of pf4 and rantes |